Efficacy Conclusions

Bosentan 125 and 250 mg bid (vs placebo):
• Increased exercise capacity
  • Consistent in all subpopulations
• Improved dyspnea on exercise
• Improved WHO functional class

9046.01

Previous slide

Next slide

Back to first slide

View graphic version